1 |
Thomas DW, Sinatra FR, Merritt RJ. Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease. Gastroenterology 1981;80:776-82.
DOI
|
2 |
Kverneland LS, Kramer P, Ovroutski S. Five decades of the Fontan operation: a systematic review of international reports on outcomes after univentricular palliation. Congenit Heart Dis 2018;13:181-93.
DOI
|
3 |
Itkin M, Piccoli DA, Nadolski G, Rychik J, DeWitt A, Pinto E, et al. Protein-losing enteropathy in patients with congenital heart disease. J Am Coll Cardiol 2017;69:2929-37.
DOI
|
4 |
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595-606.
DOI
|
5 |
Altin Z, Atabay Y, Ozer S, Karakoyun M, Ekmekci S, Yurekli EY, et al. Primary intestinal lymphangiectasia and a review of the current literature. Turk J Gastroenterol 2018;29:714-6.
|
6 |
Crossland DS, Van De Bruaene A, Silversides CK, Hickey EJ, Roche SL. Heart failure in adult congenital heart disease: from advanced therapies to end-of-life care. Can J Cardiol 2019;35:1723-39.
DOI
|
7 |
Takeda H, Ishihama K, Fukui T, Fujishima S, Orii T, Nakazawa Y, et al. Significance of rapid turnover proteins in protein-losing gastroenteropathy. Hepatogastroenterology 2003;50:1963-5.
|
8 |
Bernier JJ, Florent C, Desmazures C, Aymes C, L'Hirondel C. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978;2:763-4.
|
9 |
Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995;55:35-45.
|
10 |
Konar A, Brown CB, Hancock BW, Moss S. Protein losing enteropathy as a sole manifestation of nonHodgkin's lymphoma. Postgrad Med J 1986;62:399-400.
DOI
|
11 |
D'amico MA, Weiner M, Ruzal-Shapiro C, DeFelice AR, Brodlie S, Kazlow PG. Protein-losing enteropathy: an unusual presentation of neuroblastoma. Clin Pediatr (Phila) 2003;42:371-3.
DOI
|
12 |
Akkelle BS, Tutar E, Sengul OK, Celikel CA, Ertem D. A rare complication of giardiasis in children: protein-losing enteropathy. Pediatr Infect Dis J 2018;37:e345-7.
DOI
|
13 |
Braamskamp MJ, Dolman KM, Tabbers MM. Clinical practice. Protein-losing enteropathy in children. Eur J Pediatr 2010;169:1179-85.
DOI
|
14 |
Chavhan GB, Amaral JG, Temple M, Itkin M. MR lymphangiography in children: technique and potential applications. Radiographics 2017;37:1775-90.
DOI
|
15 |
MacLean JE, Cohen E, Weinstein M. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy. Pediatrics 2002;109:1177-80.
DOI
|
16 |
Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann Pharmacother 2000;34:1044-55.
DOI
|
17 |
Blackstone MM, Mittal MK. The edematous toddler: a case of pediatric Menetrier disease. Pediatr Emerg Care 2008;24:682-4.
DOI
|
18 |
Asakura H, Miura S, Morishita T, Aiso S, Tanaka T, Kitahora T, et al. Endoscopic and histopathological study on primary and secondary intestinal lymphangiectasia. Dig Dis Sci 1981;26:312-20.
DOI
|
19 |
Rivet C, Lapalus MG, Dumortier J, Le Gall C, Budin C, Bouvier R, et al. Use of capsule endoscopy in children with primary intestinal lymphangiectasia. Gastrointest Endosc 2006;64:649-50.
DOI
|
20 |
Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR. Modern nutrition in health and disease. 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2012.
|
21 |
Suresh N, Ganesh R, Sankar J, Sathiyasekaran M. Primary intestinal lymphangiectasia. Indian Pediatr 2009;46:903-6.
|
22 |
Kwon Y, Kim ES, Choe YH, Hyun D, Kim MJ. Therapeutic lymphatic embolization in pediatric primary intestinal lymphangiectasia. Yonsei Med J 2021;62:470-3.
DOI
|
23 |
Maleux G, Storme E, Cools B, Heying R, Boshoff D, Louw JJ, et al. Percutaneous embolization of lymphatic fistulae as treatment for protein-losing enteropathy and plastic bronchitis in patients with failing Fontan circulation. Catheter Cardiovasc Interv 2019;94:996-1002.
DOI
|
24 |
Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.
DOI
|
25 |
Suehiro K, Morikage N, Murakami M, Yamashita O, Hamano K. Late-onset primary intestinal lymphangiectasia successfully managed with octreotide: a case report. Ann Vasc Dis 2012;5:96-9.
DOI
|
26 |
Kuroiwa G, Takayama T, Sato Y, Takahashi Y, Fujita T, Nobuoka A, et al. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol 2001;36:129-32.
DOI
|
27 |
Baluk P, Yao LC, Flores JC, Choi D, Hong YK, McDonald DM. Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight 2017;2:e90103.
DOI
|
28 |
Ghobrial IM, Gertz M, LaPlant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-14.
DOI
|
29 |
Hollis IB, Reed BN, Moranville MP. Medication management of cardiac allograft vasculopathy after heart transplantation. Pharmacotherapy 2015;35:489-501.
DOI
|
30 |
Ozeki M, Hori T, Kanda K, Kawamoto N, Ibuka T, Miyazaki T, et al. Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy. Pediatrics 2016;137:e20152562.
DOI
|
31 |
Lee EW, Shin JH, Ko HK, Park J, Kim SH, Sung KB. Lymphangiography to treat postoperative lymphatic leakage: a technical review. Korean J Radiol 2014;15:724-32.
DOI
|
32 |
Wyllie R, Hyams JS, Kay M. Pediatric gastrointestinal and liver disease. 4th ed. Philadelphia: Elsevier/ Saunders, 2011.
|
33 |
Wilkinson P, Pinto B, Senior JR. Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis. N Engl J Med 1965;273:1178-81.
DOI
|
34 |
Kwon Y, Kim ES, Choe YH, Kim MJ. Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature. BMC Pediatr 2021;21:21.
DOI
|
35 |
Wagner MJ, Cranmer LD, Loggers ET, Pollack SM. Propranolol for the treatment of vascular sarcomas. J Exp Pharmacol 2018;10:51-8.
DOI
|
36 |
Prasad D, Srivastava A, Tambe A, Yachha SK, Sarma MS, Poddar U. Clinical Profile, response to therapy, and outcome of children with primary intestinal lymphangiectasia. Dig Dis 2019;37:458-66.
DOI
|
37 |
Liviskie CJ, Brennan CC, McPherson CC, Vesoulis ZA. Propranolol for the treatment of lymphatic malformations in a neonate - a case report and review of literature. J Pediatr Pharmacol Ther 2020;25:155-62.
DOI
|
38 |
Poralla C, Specht S, Born M, Muller A, Bartmann P, Muller A. Treatment of congenital generalized lymphangiectasia with propranolol in a preterm infant. Pediatrics 2014;133:e439-42.
DOI
|
39 |
Mine K, Matsubayashi S, Nakai Y, Nakagawa T. Intestinal lymphangiectasia markedly improved with antiplasmin therapy. Gastroenterology 1989;96:1596-9.
DOI
|
40 |
Chen E, Itkin M. Thoracic duct embolization for chylous leaks. Semin Intervent Radiol 2011;28:63-74.
DOI
|
41 |
Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987;109:320-6.
|